title: Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination.
abstract: Antibody responses to a 23-valent pneumococcal vaccine for Streptococcus pneumoniae serotypes 6B, 14, 19F, and 23F in 84 patients with chronic pulmonary diseases over a 2-year period after vaccination were examined by using a third-generation enzyme-linked immunosorbent assay. Of these patients, 28 (31%) were low responders who had developed increases of at least twofold in the levels of serotype-specific immunoglobulin G (IgG) in sera for none of the four serotypes at 1 month after vaccination. Although no specific clinical features of low responders were evident, their prevaccination levels of IgG for all serotypes were higher than those of responders. In responders, the levels of IgG specific for serotypes 14 and 23F in sera were greatly increased 1 month after vaccination and those specific for serotypes 6B and 19F were moderately increased. In contrast, no significant increases in the levels of IgG specific for serotypes 6B, 19F, and 23F in the low responders during the same period were found, but the levels of IgG specific for serotype 14 did increase. Although a rapid decline in the levels of IgG for all serotypes in responders between 1 month and 6 months after vaccination was found, the levels of IgG specific for serotypes 14 and 23F in sera remained higher than the prevaccination levels for at least 2 years after vaccination. These data suggest the need for the revaccination of responders but not low responders among patients with chronic pulmonary diseases. Revaccination as early as 3 years postvaccination is recommended for responders to increase the reduced levels of IgG in sera, especially those specific for the weak vaccine antigens.
authors.affiliation: Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
authors.forename: Meng
authors.initials: M
authors.lastname: Chen
authors.forename: Yuki
authors.initials: Y
authors.lastname: Hisatomi
authors.forename: Akitsugu
authors.initials: A
authors.lastname: Furumoto
authors.forename: Kenji
authors.initials: K
authors.lastname: Kawakami
authors.forename: Hironori
authors.initials: H
authors.lastname: Masaki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Nagatake
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Sueyasu
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Iwanaga
authors.forename: Hisamichi
authors.initials: H
authors.lastname: Aizawa
authors.forename: Kazunori
authors.initials: K
authors.lastname: Oishi
mesh_terms: D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D002908:Chronic Disease; D006801:Humans; D007113:Immunity, Innate; D007074:Immunoglobulin G / Q000097:blood; D008171:Lung Diseases / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013997:Time Factors
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial